Effects of adjunct galantamine to risperidone, or haloperidol, in animal models of antipsychotic activity and extrapyramidal side-effect liability: Involvement of the cholinergic muscarinic receptor

International Journal of Neuropsychopharmacology

Volumn 14, Issue 5, 2011, Pages 644-654

  Wadenberg, Marie Louise G ^a   Fjllstrm, Ann Kristin ^a   Federley, Malin ^a   Persson, Pernilla ^a   Stenqvist, Pia ^a  

^a LINNAEUS UNIVERSITY   (Sweden)

Author keywords

Antipsychotics; catalepsy; cholinergics; conditioned avoidance response; rat

Indexed keywords

GALANTAMINE; HALOPERIDOL; MUSCARINIC RECEPTOR; NICOTINIC RECEPTOR; RISPERIDONE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; COGNITION; CONTROLLED STUDY; DRUG ACTIVITY; DRUG EFFECT; DRUG MECHANISM; DRUG RECEPTOR BINDING; EXTRAPYRAMIDAL SYMPTOM; MOUSE; NONHUMAN; PRIORITY JOURNAL; PSYCHOSIS; RAT; TREATMENT OUTCOME;

ANIMALS; ANTIPSYCHOTIC AGENTS; AVOIDANCE LEARNING; BEHAVIOR, ANIMAL; CATALEPSY; CHOLINERGIC ANTAGONISTS; CHOLINESTERASE INHIBITORS; DISEASE MODELS, ANIMAL; EXTRAPYRAMIDAL TRACTS; GALANTAMINE; HALOPERIDOL; MALE; MECAMYLAMINE; MOTOR ACTIVITY; NICOTINIC ANTAGONISTS; RATS; RATS, WISTAR; RECEPTORS, MUSCARINIC; RISPERIDONE; SCHIZOPHRENIA; SCOPOLAMINE HYDROBROMIDE;

EID: 79956051888     PISSN: 14611457     EISSN: 14695111     Source Type: Journal    
DOI: 10.1017/S1461145710000921     Document Type: Article

References (53)

1. Abi-Dargham A, van de Giessen E, Slifstein M, Kegeles LS, et al. (2009). Baseline and amphetamine-stimulated dopamine activity are related in drug-nä?ve schizophrenic subjects. Biological Psychiatry 65, 1091-1093.
2. Ahlenius S, Ericson E (2001). Scopolamine does not restore normal conditioned avoidance performance in raclopride-treated rats. Journal of Neural Transmission 108, 415-430. (Pubitemid 32703891)
3. Ahlenius S, Hillegaart V (1986). Involvement of extrapyramidal motor mechanisms in the suppression of locomotor activity by antipsychotic drugs: a comparison between the effects produced by pre- and postsynaptic inhibition of dopaminergic neurotransmission. Pharmacology, Biochemistry and Behavior 24, 1409-1415. (Pubitemid 16067429)
4. Allen TB, McEvoy JP (2002). Galantamine for treatment-resistant schizophrenia. American Journal of Psychiatry 159, 1244-1245.
5. Bora E, Veznedaroglu B, Kayahan B (2005). The effect of galantamine added to clozapine on cognition of five patients with schizophrenia. Clinical Neuropharmacology 28, 139-141. (Pubitemid 40923414)
6. Buchanan RW, Conley RR, Dickinson D, Ball MP, et al. (2008). Galantamine for the treatment of cognitive impairments in people with schizophrenia. American Journal of Psychiatry 165, 82-89. (Pubitemid 351704556)
7. Conley RR, Boggs DL, Kelly DL, McMahon RP, et al. (2009). The effects of galantamine on psychopathology in chronic stable schizophrenia. Clinical Neuropharmacology 32, 69-74.
8. Cummings JL, Gorman DG, Shapira J (1993). Physostigmine ameliorates the delusions of Alzheimer's disease. Biological Psychiatry 33, 536-541. (Pubitemid 23167221)
9. Dyer MA, Freudenreich O, Culhane MA, Pachas GN, et al. (2008). High-dose galantamine augmentation inferior to placebo on attention, inhibitory control and working memory performance in nonsmokers with schizophrenia. Schizophrenia Research 102, 88-95.
10. Farde L, Nordström A-L, Wiesel F-A, Pauli S, et al. (1992). Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine: relation to extrapyramidal side effects. Archives of General Psychiatry 49, 538-544.
11. Freedman R, Olincy A, Buchanan RW, Harris JG, et al. (2008). Initial phase 2 trial of a nicotinic agonist in schizophrenia. American Journal of Psychiatry 165, 1040-1047.
12. Frey KA, Ehrenkaufer RL, Beaucage S, Agranoff BW (1985). Quantitative in vivo receptor binding. I. Theory and application to the muscarinic cholinergic receptor. Journal of Neuroscience 5, 421-428. (Pubitemid 15133159)
13. Geerts H, Guillaumat P-O, Grantham C, Bode W, et al. (2005). Brain levels and acetylcholinesterase inhibition with galantamine and donepezil in rats, mice, and rabbits. Brain Research 1033, 186-193. (Pubitemid 40193413)
14. Goldberg ME, Johnson HE, Knaak JB, Smyth HF (1963). Psychopharmacological effects of reversible cholinesterase inhibition induced by N-methyl 3-isopropyl phenyl carbamate (compound 10854). Journal of Pharmacology and Experimental Therapeutics 141, 244-252.
15. Green MF (2007). Cognition, drug treatment and functional outcome in schizophrenia: a tale of two transitions. American Journal of Psychiatry 164, 992-994. (Pubitemid 47121382)
16. Hajós M, Rogers BN (2010). Targeting alpha7 nicotinic acetylcholine receptors in the treatment of schizophrenia. Current Pharmacological Design 16, 538-554.
17. Hoebel BG, Avena NM, Rada P (2007). Accumbens dopamine-acetylcholine balance in approach and avoidance. Current Opinion in Pharmacology 7, 617-627. (Pubitemid 350177561)
18. Hohnadel E, Bouchard K, Terry AV (2007). Galantamine and donepezil attenuate pharmacologically induced deficits in prepulse inhibition in rats. Neuropharmacology 52, 542-551. (Pubitemid 46123371)
19. Jones CK, Shannon HE (2000). Muscarinic cholinergic modulation of prepulse inhibition of the acoustic startle reflex. Journal of Pharmacology and Experimental Therapeutics 294, 1017-1023. (Pubitemid 30666854)
20. Kane JM, Marder SR, Schooler NR, Wirshing WC, et al. (2001). Clozapine and haloperidol in moderately refractory schizophrenia: a 6-month randomized and double-blind comparison. Archives of General Psychiatry 58, 965-972. (Pubitemid 32937920)
21. Kapur S, Zipursky RB, Remington G, Houle S (2000). Relationship between dopamine D2 receptor occupancy, clinical response and side effects - a double blind PET study in first episode schizophrenia. American Journal of Psychiatry 157, 514-520. (Pubitemid 30191189)
22. Keefe RSE, Malhotra AK, Meltzer H, Kane JM, et al. (2008). Efficacy and safety of donepezil in patients with schizophrenia or schizoaffective disorder: significant placebo/practice effects in a 12-week, randomized, double-blind, placebo-controlled trial. Neuropsychopharmacology 33, 1217-1228. (Pubitemid 351521707)
23. Laruelle M, Abi-Dargham A, van Dyck CH, Gil R, et al. (1996). Single photon emission computerized tomography imaging of amphetamine-induced dopamine release in drug-free schizophrenic subjects. Proceedings of the National Academy of Sciences USA 93, 9235-9240.
24. Lee S-W, Lee J-G, Lee B-J, Kim YH (2007). A 12-week, double-blind, placebo-controlled trial of galantamine adjunctive treatment to conventional antipsychotics for the cognitive impairments in chronic schizophrenia. International Clinical Psychopharmacology 22, 63-68.
25. Li CC (1964). Introduction to Experimental Statistics (pp. 207-226). New York: McGraw-Hill.
26. + channels reduces autonomous activity in striatal cholinergic interneurons. Journal of Neuroscience 24, 10289-10301. (Pubitemid 39552612)
27. Meltzer HY, Alphs L, Green AI, Altamura AC, et al. (2003). Clozapine treatment for suicidality in schizophrenia: international suicide prevention trial (InterSePT). Archives of General Psychiatry 60, 82-91. (Pubitemid 36070868)
28. Meltzer HY, McGurk SR (1999). The effects of clozapine, risperidone, and olanzapine on cognitive function in schizophrenia. Schizophrenia Bulletin 25, 233-255. (Pubitemid 29272503)
29. Papke RL, Sanberg PR, Shytle RD (2001). Analysis of mecamylamine stereoisomers on human nicotinic receptor subtypes. Journal of Pharmacology and Experimental Therapeutics 297, 646-656. (Pubitemid 32377996)
30. Rabenstein RL, Caldarone BJ, Picciotto MR (2006). The nicotinic antagonist mecamylamine has antidepressant-like effects in wild-type but not beta2- or alpha7-nicotinic acetylcholine receptor subunit knockout mice. Psychopharmacology 189, 395-401. (Pubitemid 44772820)
31. Rosse RB, Deutsch SI (2002). Adjuvant galantamine administration improves negative symptoms in a patient with treatment-refractory schizophrenia. Clinical Neuropharmacology 25, 272-275. (Pubitemid 35239487)
32. Samochocki M, Höffle A, Fehrenbacher A, Jostock R, et al. (2003). Galantamine is an allosterically potentiating ligand of neuronal nicotinic but not of muscarinic acetylcholine receptors. Journal of Pharmacology and Experimental Therapeutics 305, 1024-1036. (Pubitemid 36617980)
33. Schilström B, Ivanov VB, Wiker C, Svensson TH (2007). Galantamine enhances dopaminergic neurotransmission in vivo via allosteric potentation of nicotinic acetylcholine receptors. Neuropsychopharmacology 32, 43-53. (Pubitemid 44967783)
34. Schubert MH, Young KA, Hicks PB (2006). Galantamine improves cognition in schizophrenic patients stabilized on risperidone. Biological Psychiatry 60, 530-533. (Pubitemid 44402376)
35. Shannon HE, Hart JC, Bymaster FP, Calliegaro DO, et al. (1999). Muscarinic receptor agonists, like dopamine receptor antagonist antipsychotics, inhibit conditioned avoidance response in rats. Journal of Pharmacology and Experimental Therapeutics 290, 901-907. (Pubitemid 29355112)
36. Shekhar A, Potter WZ, Lightfoot J, Lienemann J, et al. (2008). Selective muscarinic receptor agonist xanomeline as a novel treatment approach for schizophrenia. American Journal of Psychiatry 165, 1033-1039.
37. Siegel S, Castellan NJ (1988). Nonparametric Statistics for the Behavioral Sciences (pp. 87-95, 174-183). New York: McGraw-Hill.
38. Simosky JK, Stevens KE, Adler LE, Freedman R (2003). Clozapine improves deficient inhibitory auditory processing in DBA/2 mice, via a nicotinic cholinergic mechanism. Psychopharmacology 165, 386-396. (Pubitemid 36223080)
39. Stanilla JK, Simpson GM (1998). Treatment of extrapyramidal side effects. In: Schatzberg AF, Nemeroff CB (Eds), Textbook of Psychopharmacology (pp. 349-375). Washington, DC: American Psychiatric Press.
40. Stephens SH, Logel J, Barton A, Franks A, et al. (2009). Association of the 5'-upstream regulatory region of the alpha7 nicotinic acetylcholine receptor subunit gene (CHRNA7) with schizophrenia. Schizophrenia Research 109, 102-112.
41. Stone CA, Torchiana ML, Navarro A, Beyer KH (1956). Ganglionic blocking properties of 3-methylaminoisocamphane hydrochloride (mecamylamine): a secondary amine. Journal of Pharmacology 117, 169-183.
42. Sur C, Mallorga PJ, Wittmann M, Jacobson MA, et al. (2003). N-desmethylclozapine, an allosteric agonist at muscarinic 1 receptor, potentiates N-methyl-D-aspartate receptor activity. Proceedings of the National Academy of Sciences USA 100, 13674-13679. (Pubitemid 37444798)
43. Svensson TH (2003). Alpha2-Adrenoceptor modulation hypothesis of antipsychotic atypicality. Progress in Neuro-Psychopharmacology & Biological Psychiatry 27, 1145-1158. (Pubitemid 37464959)
44. Tregellas JR, Olincy A, Johnson L, Tanabe J, et al. (2010). Functional magnetic resonance imaging of effects of a nicotinic agonist in schizophrenia. Neuropsychopharmacology 35, 938-942.
45. Vanover KE, Veinbergs I, Davis RE (2008). Antipsychotic-like behavioral effects and cognitive enhancement by a potent and selective muscarinic M1 receptor agonist, AC-260584. Behavioral Neuroscience 122, 570-575. (Pubitemid 351787835)
46. Wadenberg M-L, Ericsson E-L, Magnusson O, Ahlenius S (1990). Suppression of conditioned avoidance behavior by the local application of (-)sulpiride into the ventral, but not the dorsal, striatum of the rat. Biological Psychiatry 28, 297-307. (Pubitemid 20253246)
47. 2 receptor occupancy is a common mechanism underlying animal models of anipsychotics and their clinical effects. Neuropsychopharmacology 25, 633-641. (Pubitemid 32995945)
48. Wadenberg M-LG (2010). Conditioned avoidance response in the development of new antipsychotics. Current Pharmaceutical Design 16, 358-370.
49. Wang D, Noda Y, Zhou Y, Nitta A, et al. (2007). Synergistic effect of galantamine with risperidone on impairment of social interaction in phencyclidine-treated mice as a schizophrenic animal model. Neuropharmacology 52, 1179-1187.
50. Weinberger DR, Egan MF, Bertolino A, Callicott JH, et al. (2001). Prefrontal neurons and the genetics of schizophrenia. Biological Psychiatry 50, 825-844. (Pubitemid 34020697)
51. Weiner DM, Meltzer HY, Veinbergs I, Donohue EM, et al. (2004). The role of M1 muscarinic receptor agonism of N-desmethylclozapine in the unique clinical effects of clozapine. Psychopharmacology 177, 207-216. (Pubitemid 40109932)
52. Wiker C, Schilström B, Sandbäck C, Wadenberg M-L, et al. (2008). Adjunctive galantamine, but not donepezil, enhances the antipsychotic-like effect of raclopride in rats. International Journal of Neuropsychopharmacology 11, 845-850.
53. Yeomans JS (1995). Role of tegmental cholinergic neurons in dopaminergic activation, antimuscarinic psychosis and schizophrenia. Neuropsychopharmacology 12, 3-16.